Histogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference
March 29 2017 - 08:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, today announced that Adam Gridley,
Chief Executive Officer of Histogenics, will be presenting a
corporate overview at Needham & Company’s 16th Annual
Healthcare Conference on, April 5, 2017 at 09:20 AM EDT at the
Westin Grand Central Hotel in New York, NY.
This presentation will be webcast live and may be accessed by
visiting the Investor Relations section of Histogenics’ website at
www.histogenics.com. The webcast will be available on
Histogenics’ website for 30 days following the conference.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing products in the
musculoskeletal segment of the marketplace. Histogenics’
regenerative medicine platform combines expertise in cell
processing, scaffolding, tissue engineering, bioadhesives and
growth factors to provide solutions to treat
musculoskeletal-related conditions. Histogenics’ first
investigational product candidate, NeoCart®, is currently in Phase
3 clinical development. NeoCart is an autologous cell therapy
designed to treat cartilage defects in the knee using the patient’s
own cells. Knee cartilage defects represent a significant
opportunity in the United States, with an estimated 500,000 or more
applicable procedures each year. NeoCart is designed to
exhibit characteristics of articular, hyaline cartilage prior to
and upon implantation into the knee and therefore does not rely on
the body to make new cartilage, characteristics not exhibited in
other current treatment options. For more information, please
visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Mar 2023 to Mar 2024